Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees by Takehisa, Jun et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generation of infectious molecular clones of simian
immunodeficiency virus from fecal consensus sequences of wild
chimpanzees
Citation for published version:
Takehisa, J, Kraus, MH, Decker, JM, Li, Y, Keele, BF, Bibollet-Ruche, F, Zaammit, KP, Weng, Z, Santiago,
ML, Kamenya, S, Wilson, ML, Pusey, AE, Bailes, E, Sharp, PM, Shaw, GM & Hahn, BH 2007, 'Generation
of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild
chimpanzees' Journal of Virology, vol 81, no. 14, pp. 7463-7475. DOI: 10.1128/JVI.00551-07
Digital Object Identifier (DOI):
10.1128/JVI.00551-07
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Virology
Publisher Rights Statement:
Free in PMC.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
JOURNAL OF VIROLOGY, July 2007, p. 7463–7475 Vol. 81, No. 14
0022-538X/07/$08.000 doi:10.1128/JVI.00551-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
Generation of Infectious Molecular Clones of Simian Immunodeficiency
Virus from Fecal Consensus Sequences of Wild Chimpanzees
Jun Takehisa,1 Matthias H. Kraus,1 Julie M. Decker,1 Yingying Li,1 Brandon F. Keele,1
Fre´deric Bibollet-Ruche,1 Kenneth P. Zammit,1 Zhiping Weng,1 Mario L. Santiago,2
Shadrack Kamenya,3 Michael L. Wilson,3 Anne E. Pusey,4 Elizabeth Bailes,5
Paul M. Sharp,5 George M. Shaw,1,6 and Beatrice H. Hahn1,6*
Departments of Medicine1 and Microbiology,6 University of Alabama at Birmingham, Birmingham, Alabama 35294;
Gladstone Institute of Virology and Immunology, San Francisco, California 941582; Gombe Stream Research Centre,
The Jane Goodall Institute, Kigoma, Tanzania3; Department of Ecology, Evolution and Behavior, University of
Minnesota, St. Paul, Minnesota 551084; and Institute of Genetics, University of Nottingham,
Queens Medical Centre, Nottingham, United Kingdom5
Received 15 March 2007/Accepted 30 April 2007
Studies of simian immunodeficiency viruses (SIVs) in their endangered primate hosts are of obvious medical
and public health importance, but technically challenging. Although SIV-specific antibodies and nucleic acids
have been detected in primate fecal samples, recovery of replication-competent virus from such samples has
not been achieved. Here, we report the construction of infectious molecular clones of SIVcpz from fecal viral
consensus sequences. Subgenomic fragments comprising a complete provirus were amplified from fecal RNA
of three wild-living chimpanzees and sequenced directly. One set of amplicons was concatenated using overlap
extension PCR. The resulting clone (TAN1.24) contained intact genes and regulatory regions but was repli-
cation defective. It also differed from the fecal consensus sequence by 76 nucleotides. Stepwise elimination of
all missense mutations generated several constructs with restored replication potential. The clone that yielded
the most infectious virus (TAN1.910) was identical to the consensus sequence in both protein and long terminal
repeat sequences. Two additional SIVcpz clones were constructed by direct synthesis of fecal consensus
sequences. One of these (TAN3.1) yielded fully infectious virus, while the second one (TAN2.69) required
modification at one ambiguous site in the viral pol gene for biological activity. All three reconstructed
proviruses produced infectious virions that replicated in human and chimpanzee CD4 T cells, were CCR5
tropic, and resembled primary human immunodeficiency virus type 1 isolates in their neutralization pheno-
type. These results provide the first direct evidence that naturally occurring SIVcpz strains already have many
of the biological properties required for persistent infection of humans, including CD4 and CCR5 dependence
and neutralization resistance. Moreover, they outline a new strategy for obtaining medically important “SIV
isolates” that have thus far eluded investigation. Such isolates are needed to identify viral determinants that
contribute to cross-species transmission and host adaptation.
Of all human infectious diseases that have emerged in recent
history, AIDS is one of the most devastating. With more than
65 million people infected and over 25 million deaths, human
immunodeficiency virus type 1 (HIV-1) represents one of the
most serious public health threats of the 21st century (11).
There are three major variants of HIV-1, termed groups M, N,
and O, which are the result of independent cross-species trans-
mission events of simian immunodeficiency viruses (SIVcpz/
SIVgor) that naturally infect chimpanzees (Pan troglodytes
troglodytes) and gorillas (Gorilla gorilla gorilla) in west central
Africa (22, 31, 51, 54). Although each cross-species transmis-
sion generated an AIDS-causing pathogen, the subsequent
spread of these infections in the human population has been
variable (22, 51, 58). Group M is the cause of the vast majority
of HIV-1 infections worldwide and the source of the AIDS
pandemic (9, 23, 35). In contrast, group N and O infections
account for a much smaller fraction of AIDS cases and are
restricted to west central Africa (1, 7, 44, 61, 62). To elucidate
the circumstances of their emergence, recent efforts have fo-
cused on characterizing their natural ape reservoirs. These
studies have traced the closest SIV relatives of HIV-1 group M
to geographically isolated chimpanzee (P. t. troglodytes) com-
munities in southeastern Cameroon (31). The closest SIV rel-
atives of HIV-1 group N have also been identified in wild-living
chimpanzees, but in P. t. troglodytes communities in south-
central Cameroon (31). Finally, HIV-1 group O-like viruses
have been identified in western lowland gorillas (G. g. gorilla)
(54). Since these gorilla viruses are also of P. t. troglodytes
origin, gorillas may have served as an intermediary host for the
human infection. Alternatively, P. t. troglodytes apes harboring
group O-like viruses may have been the source of independent
gorilla and human infections (54).
Previous studies have classified common chimpanzees into
four subspecies on the basis of differences in mitochondrial
DNA sequences, including P. t. verus in west Africa; P. t.
vellerosus in Nigeria and northern Cameroon; P. t. troglodytes in
southern Cameroon, Gabon, Equatorial Guinea, and the Re-
public of Congo; and P. t. schweinfurthii in the Democratic
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Republic of Congo, Uganda, Rwanda, Burundi, and Tanzania
(10). Although the validity of this taxonomy has recently been
questioned by primatologists (17), the differentiation of chim-
panzees into geographically isolated populations has been of
use to virologists. For example, of the four previously defined
subspecies only P. t. troglodytes and P. t. schweinfurthii apes are
naturally infected with SIVcpz (51). Moreover, their viruses
fall into two divergent lineages (SIVcpzPtt and SIVcpzPts) that
differ in up to 40% of their nucleotide sequences and exhibit
lineage-specific protein signatures (46, 48). This extent of ge-
netic diversity is comparable to that observed for SIVs from
related monkey species (2, 24). However, the divergence of
SIVcpzPtt and SIVcpzPts strains does not reflect different or-
igins. Evolutionary studies have shown that SIVcpz has a mo-
saic genome structure comprising SIV lineages infecting mon-
key species on which chimpanzees prey (3). Since all known
SIVcpz strains exhibit the same mosaic genome structure, it is
clear that they share a common ancestry. The observed diver-
sity between the SIVcpzPtt and SIVcpzPts lineages must there-
fore reflect their evolution in geographically isolated hosts.
Thus, until a new taxonomy is formally adopted, we will use the
existing subspecies designations to describe SIVcpz infection in
distinct chimpanzee populations.
Although the origins of the AIDS pandemic have now been
determined, important questions remain concerning the cir-
cumstances of the cross-species transmission events and the
factors that contributed to HIV-1’s emergence. In particular, it
is perplexing that only certain strains of SIVcpzPtt, but not of
SIVcpzPts, have been found in humans. Recent surveys of
wild-living P. t. schweinfurthii apes in the Democratic Republic
of Congo have shown that SIVcpzPts is as widely distributed as
SIVcpzPtt, with high levels of endemicity in some communities
and rare or absent infection in others (48, 59; Y. Li and B. H.
Hahn, unpublished). Thus, the lack of SIVcpzPts-like viruses in
humans cannot be explained by a paucity of naturally occurring
SIVcpzPts infections. It is possible that environmental factors
and/or human behavior may have rendered SIVcpzPts trans-
missions less likely. It is also possible that SIVcpzPts transmis-
sions have occurred but subsequently gone extinct. However,
given the genetic diversity of SIVcpzPts and SIVcpzPtt strains,
viral properties may also have played a role. The latter possi-
bility is testable but requires a panel of diverse SIVcpzPtt and
SIVcpzPts isolates for detailed biological characterization. To
date, only five SIVcpz isolates and one infectious molecular
clone have been obtained, all of which were derived by in vitro
cultivation (13, 38, 40, 41). Four of these (GAB1, CAM3,
CAM5, and CAM13) are from P. t. troglodytes apes, while the
fifth represents the only SIVcpzPts (ANT) isolate (51). The
single infectious molecular clone of SIVcpz (GAB1) was de-
rived from a productively infected human lymphocyte culture
(28). Given that all existing SIVcpz isolates have been adapted
to growth in human T cells, they are not suitable for studies
aimed at identifying viral determinants of host adaptation.
Given the highly endangered status of chimpanzees and
gorillas throughout equatorial Africa, obtaining blood samples
for virus isolation studies from wild-living apes is neither eth-
ical nor practical. We recently developed noninvasive methods
that permit the detection of virus-specific antibodies and nu-
cleic acids in RNAlater-preserved fecal samples collected from
the forest floor (46–50, 59). While this approach has been
instrumental in determining the prevalence, geographic distri-
bution, and evolutionary history of SIVs infecting wild chim-
panzee, gorilla, and sooty mangabey populations (31, 49, 54), it
is not suitable for isolation of infectious virus. In this paper, we
have thus explored an alternative approach. Reasoning that
virion RNA must represent the progeny of recent virus infec-
tion and expression, we constructed SIVcpzPts genomes based
on viral consensus sequences present in the feces of three
wild-living P. t. schweinfurthii apes. Our results show that this
form of virus recovery indeed yielded infectious SIVcpz mo-
lecular clones, thus providing proof of concept for a new iso-
lation strategy applicable especially to situations when direct
human-animal contact is infrequent or discouraged.
MATERIALS AND METHODS
Chimpanzee samples. The amplification and sequence analysis of the TAN1
genome from a wild chimpanzee in Gombe National Park, Tanzania (Ch-06)
have previously been reported (46). To amplify two additional SIVcpz genomes,
fecal samples were obtained from a female member of the nonhabituated Ka-
lande community (Ch-64, sampled 11 November 2001) and a high-ranking male
member of the Mitumba community (Ch-45, sampled 3 January 2002). These
two chimpanzees had previously been shown to harbor divergent strains of
SIVcpzPts, termed TAN2 and TAN3, respectively (48). Fecal RNA was extracted
using the RNAqueous Midi-Kit (Ambion, Austin, TX) as described previously
(31, 46, 48, 54).
Generation of fecal SIVcpzPts population sequences. TAN2 and TAN3 full-
length fecal consensus sequences were obtained by amplifying and sequencing
partially overlapping subgenomic fragments (367 bp to 2,197 bp) from fecal RNA
as described previously (46). Briefly, cDNA was synthesized by adding fecal viral
RNA (10 l) to a reverse transcriptase PCR (RT-PCR) master mixture contain-
ing 1 buffer (Invitrogen; Carlsbad, CA), 0.5 mM deoxynucleoside triphosphate
(dNTP), 5 mM dithiothreitol, 2 pmol of primer, 20 U of RNase inhibitor (Am-
bion), and 200 U of SuperScript RT III (Invitrogen) and by incubating the
mixture for 1 h at 50°C. cDNA (10 l) was then added to a PCR mixture
consisting of 1 Expand Buffer II (Roche Diagnostics, Indianapolis, IN), 0.2 mM
dNTP, 300 nM of first-round PCR primers, 25 g of bovine serum albumin, and
2.6 U of Expand high-fidelity polymerase mixture (Roche Diagnostics). Ampli-
fication conditions for both first- and second-round PCRs included 45 cycles of
denaturation (94°C, 0.5 min), annealing (50°C, 0.5 min), and extension (68°C, 1
min). Amplicons were gel purified and sequenced directly using an ABI 3730
DNA analyzer. Population sequences were analyzed using Sequencher version
4.6 (Gene Codes Corporation, Ann Arbor, MI), and chromatograms were care-
fully examined for positions of base mixtures.
Construction of SIVcpzPts proviral clones. The TAN1.24 provirus was gener-
ated by concatenating 13 RT-PCR products using extension overlap PCR (16,
65). Amplicons were linked in a stepwise manner using the GeneAmp high-
fidelity PCR system (Applied Biosytems, Foster City, CA) as shown in Fig. 1.
Each concatenation reaction included 30 cycles of denaturation (94°C, 15 s),
annealing (55°C, 30 s), and extension (68°C, 2 to 5 min). PCR products repre-
senting the 5 and 3 halves of the TAN1 genome were subcloned into pCR-XL
TOPO (Invitrogen) and ligated to generate a complete provirus (TAN1.24).
TAN2 and TAN3 proviruses were chemically synthesized (purchased from
Blue Heron Biotechnology, Bothell, WA) using their DNA consensus sequences
as a guide (see Results). Synthesized 3 and 5 proviral halves were subcloned in
pCR-XL TOPO and ligated to generate full-length proviral clones, termed
TAN2.1 and TAN3.1, respectively.
Large-scale plasmid preparation. Plasmid clones containing full-length SIVcpzPts
genomes were propagated in STBL2 (Invitrogen) cells at 30°C in a Forma orbital
benchtop shaker (model 420/2l) using 2-liter disposable Erlenmeyer flasks
(Corning; 16 cm diameter, vented caps) at low levels of agitation (225 rounds per
minute). Bacterial cultures were harvested prior to reaching saturating growth
density and purified endotoxin free (QIAGEN, Valencia, CA). Because proviral
plasmid clones are inherently unstable, each large-scale plasmid preparation was
completely sequenced prior to use in biological experiments. All replication-
competent SIVcpzPts (TAN1.910, TAN2.69, and TAN3.1) clones have been
submitted to the National Institutes of Health Research and Reference Program
(Rockville, MD).
Site-directed mutagenesis. Site-directed mutagenesis of the TAN1.24 clone
was performed using the QuikChange XL site-directed mutagenesis kit (Strat-
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agene, La Jolla, CA). Up to 3 nucleotide substitutions were introduced simul-
taneously. Mutagenesis primers (15 pmol each) complementary to both DNA
strands and containing the intended mutations were mixed with 5 to 10 fmol of
supercoiled plasmid DNA as the template. PCR amplification was conducted for
50 s at 95°C, 50 s at 60°C, and 9 min at 68°C. Following 18 amplification cycles,
template DNA was digested by methylation-specific cleavage using 10 U of DpnI.
Unmethylated circular plasmid DNA containing the primer-mediated mutations
was used for transformation of STBL2 cells (Invitrogen). Half-genome clones
were directionally ligated into PCR-XL TOPO, and proviral constructs were
confirmed by nucleotide sequence analysis.
Site-directed mutagenesis was also used to replace a guanine at position 3057
in the TAN2.1 genome with an adenine. Recombinant PCR was used to intro-
duce this single nucleotide substitution, which was centered within the overlap of
two primary amplification products using the following primers (mutations un-
derlined and in boldface): F1 (5-CAGAGAGTTAAATAAGAGAACTCAGG
A-3), R1 (5-GGTCAGTCAATCCCTTTACTCCTCTAATTAG-3), F2 (5-C
TAATTAGAGGAGTAAAGGGATTGACTGACC-3), and R2 (5-CTGCTGC
ACTAGTAAAGTTTGGCCCATTATC-3). The two fragments were then
linked by overlap extension PCR using 30 fmol of each amplicon and nested
outside primers (F3, 5-GGAACATGGTAACAGTGCTGGATGTAGG-3,
and R3, 5-GGTATGACCTCTGCTTCTAGGAAACCAC-3) using the follow-
ing conditions: 3 cycles of 1 min at 95°C, a 2-min ramp from 37°C to 72°C, and
2 min at 72° followed by 15 cycles of 1 min at 95°C, 1 min at 60°C, and 2 min at
72°C. The resulting fragment was cloned into TAN2.1 using unique BstZ171 and
PshAI restriction enzyme sites to generate TAN2.69.
Phylogenetic analyses. SIVcpzTAN2 and -TAN3 were compared to represen-
tative members of the HIV-1/SIVcpz lineage using the following full-length
proviral sequences (GenBank accession numbers are in parentheses): HIV-1
group M, U455A, subtype A (M62320), and BRU, subtype B (K02013); HIV-1
group N, YBF30 (AJ006022) and YBF106 (AJ271370); HIV-1 group O,
MVP5180 (L20571) and ANT70 (L20587); SIVcpzPtt, LB7 (DQ373064), MB66
(DQ373063), EK505 (DQ373065), MT145 (DQ373066), CAM3 (AF115393),
CAM5 (AJ271369), CAM13 (AY169968), GAB1 (X52154), GAB2 (AF382828),
and US (AF103818); SIVcpzPts, ANT (U42720) and TAN1 (AF447763). Amino
acid sequences were aligned using CLUSTAL W (52). Sites that could not be
aligned unambiguously or sites with a gap in any sequence were excluded. For
full-length genome analysis, Gag/Pol and Pol/Vif overlaps were removed from
the C termini of the deduced Gag and Pol protein sequences, respectively. Trees
were inferred by the Bayesian method (64) implemented in MrBayes version 3.1
(27) using the Jones et al. matrix (29) with gamma-distributed rates at sites (63)
and 1 million generations. Average standard deviation of split frequencies was
0.002.
Transfection-derived viral stocks. Full-length SIVcpz and HIV-1 proviral
clones were transfected into 293T cells using the Lipofectin-based FuGene6
reagent (Roche Diagnostics). Supernatants were collected 48 to 72 h following
transfection and clarified by low-speed centrifugation. Cell-free virus stocks were
stored in aliquots at 80°C.
To determine particle-associated RT activity, supernatants (1 to 5 ml) were
pelleted at 40,000  g for 1 h at 4°C, solubilized in lysis buffer, titrated using
serial 10-fold dilutions, and analyzed using a colorimetric enzyme-linked immu-
nosorbent assay (Roche Diagnostics). RT activity was determined by quantitative
immunodetection of digoxigenin-labeled nucleotides incorporated during cDNA
synthesis using a homopolymeric poly(A)/oligo(dT) primer complex. Back-
ground RT activity was measured in supernatants of mock-transfected cells and
subtracted. The amount of enzymatic activity (expressed as ng RT/ml) was
determined using the linear range of a standard curve generated from decreasing
amounts (2 ng to 3 pg) of recombinant HIV-1 RT analyzed in parallel (Roche
Diagnostics).
Single-round infectivity assay and coreceptor usage. Viral infectivity was
tested using JC53-BL cells, which express high levels of CD4, CXCR4, and
CCR5 and also harbor Tat-responsive reporter genes for Escherichia coli -ga-
lactosidase as well as firefly luciferase under the control of an HIV-1 long
terminal repeat (LTR) sequence (14, 42, 56). JC53-BL cells were seeded in
24-well plates at a density of 50,000 cells/well in Dulbecco’s modified Eagle
medium (DMEM) containing 10% fetal bovine serum 24 h prior to infection.
Serial dilutions of virus stocks were added in a final volume of 250 l/well
containing 40 g/ml DEAE-dextran (Sigma-Aldrich, St. Louis, MO). Forty-eight
hours postinfection, plates were stained, and -galactosidase-positive cells were
counted. Infectivity (infectious units [IU]/ml) scored at different dilutions was
averaged and standardized based on particle-associated RT activity of viral input
(IU/ng RT).
JC53-BL cells were also used to determine the coreceptor preference of the
reconstructed viruses. Cells were seeded at 8,300 cells/well in 96-well plates
overnight and then treated with AMD3100 (1.2 M), TAK-779 (10 M), or a
combination of both for 1 h. Virus was added (1 ng of particle-associated RT 
2,000 IU) in the presence of 40 g/ml DEAE-dextran. After 48 h of incubation
at 37°C, supernatant was removed, and cells were processed for detection of
luciferase activity according to the manufacturer’s recommendations (Promega,
Madison, WI). Light intensity of cell lysates was quantitated using a Tropix
luminometer and WinGlow version 1.24 software.
Chimpanzee and human PBMC cultures. Blood was obtained from healthy
(HIV-1-uninfected) human volunteers (Research Blood Components, Boston,
MA) as well as uninfected chimpanzees housed at the Yerkes Regional Primate
Research Center. Chimpanzee blood was collected from anesthetized individuals
FIG. 1. Construction of a full-length SIVcpzPts provirus by concatenation of subgenomic RT-PCR fragments. RT-PCR products (open boxes)
previously reported to comprise the complete TAN1 genome (46) are shown in relation to sequential concatenation products (gray boxes)
generated by extension overlap PCR. All fragments are drawn to scale, and the derivation of each concatenation product is indicated by capital
letters. The final amplicons comprising 5 (4,304-bp) and 3 (5,608-bp) proviral halves were ligated at an internal BsmBI site, generating the
TAN1.24 provirus. Nucleotide sequences are numbered starting at the beginning of the R region in the 5 LTR (see scale bar).
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as part of their annual health survey, a procedure approved by the Emory
Institutional Animal Care and Use Committee. Peripheral blood mononuclear
cells (PBMCs) were isolated by density separation using Ficoll-Hypaque Plus
(GE Healthcare, Piscataway, NJ) and centrifuged at 1,800 rpm for 25 min at
22°C. Buffy coat cells were washed once at room temperature in Hanks balanced
saline solution (HBSS) plus 4 mM EDTA and once at 4°C in HBSS plus 1% fetal
calf serum (FCS). CD4 cells were enriched using CD4-containing microbeads
and magnetic cell sorting (Militenyi Biotec, Auburn, CA). For activation, CD4
cells were allowed to adhere in six-well plates for 30 min and then stimulated for
12 to 15 h with 3 g/ml of staphylococcal enterotoxin B (Sigma-Aldridge, St.
Louis, MO) in RPMI medium plus 15% FCS. Cells were washed once with
HBSS, resuspended in DMEM with 10% giant cell tumor-conditioned media
(BioVeris Corp., Gaithersburg, MD) and 10% human AB serum (Fisher Biore-
agents, Fair Lawn, NJ), returned to the same well in which they were activated,
and incubated for 5 to 6 days at 37°C. Cells were placed in DMEM containing
10% FCS and 30 U/ml interleukin-2 (IL-2) 1 day prior to infection. One million
stimulated CD4 cells were incubated with transfection-derived viral stocks
equilibrated by particle-associated RT activity (50 ng) in 300 l DMEM con-
taining 10% FCS and 30 U/ml IL-2 for 16 h at 37°C. Cells were washed three
times with HBSS and plated on 24-well plates in 2 ml DMEM/well containing
10% FCS and 30 U/ml IL-2. To determine viral growth kinetics, 20-l aliquots of
supernatant were collected on the first day and every other day thereafter
following cell seeding and analyzed for RT activity.
Immunoblot analysis. The protein content of SIVcpz and HIV-1 virions was
examined by immunoblotting using anti-HIV-1 Gag-, Pol-, and Env-specific
antibodies. Cell-free supernatants of transfected 293T cells were pelleted. Viri-
ons were solubilized in StaphA buffer (25 mM sodium phosphate buffer, pH 7.4,
100 mM NaCl, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.5% deoxy-
cholate, 5 mM EGTA) containing 1 mM phenylmethylsulfonyl fluoride and 10
g/ml aprotinin protease inhibitors. Viral proteins were separated on 4 to 12%
precast Bis-Tris polyacrylamide gradient gels (Invitrogen) and transferred to
polyvinylidene difluoride membranes (Millipore, Bedford, MA) by electro-
blotting. Protein loading was equilibrated by RT activity. Membrane blocking
and antibody treatment were conducted in Tris-buffered saline, pH 7.4 (TBS),
containing 0.05% Tween 20 and 5% nonfat dry milk. Membranes were washed
three times following antibody incubations in TBS containing 0.05% Tween 20
and once in detergent-free TBS prior to addition of chemiluminescent substrate.
Bound antibodies were visualized with horseradish peroxidase-conjugated sec-
ondary antibodies (Pierce, Rockford, IL, and Southern Biotech, Birmingham,
AL), followed by West Femto chemiluminescence detection (Pierce). Polyclonal
rabbit anti-HIV-1 p24 (4250) and integrase (756) (21) antibodies were obtained
through the NIH AIDS Research and Reference Reagent Program and used at
dilutions of 1:50,000 and 1:2,000, respectively. An anti-HIV-1 RT antiserum was
provided by X. Wu and J. Kappes (18) and used at a dilution of 1:8,000. Finally,
an anti-SIVcpzPts gp120 antiserum generated in immunized guinea pigs (see
below) was used at a dilution of 1:2,000.
Generation of SIVcpzPts lineage-specific anti-gp120 antibodies. SIVcpzPts
Env proteins cross-react only poorly with anti-HIV-1 Env antibodies. To permit
detection of the TAN1.910, TAN2.69, and TAN3.1 Env proteins on immuno-
blots, we raised SIVcpzPts Env-specific antisera in guinea pigs. Guinea pigs were
housed according to Accreditation of Laboratory Animal Care guidelines. Two
female Hartley guinea pigs (Harlan Sprague, Indianapolis, IN) were immunized
intramuscularly six times at 3-week intervals with 400 g of a codon usage-
optimized TAN1 env (gp160) plasmid (donated to the National Institutes of
Health Research and Reference Program). Subsequently, animals were boosted
twice at 3-week intervals with 50 g of recombinant TAN1 gp120 protein in the
presence of trehalose dicorynomycolate adjuvant (1:1, vol/vol; Sigma; M6536).
Recombinant TAN1 gp120 protein was generated by transfection of 293T cells
with a codon usage-optimized TAN1 gp120 env expression vector purified from
serum-free medium 72 h following transfection by lectin affinity chromatography,
dialyzed against phosphate-buffered saline, and concentrated by membrane cen-
trifugation (700-kDa cutoff).
Nucleotide sequence accession numbers. GenBank accession numbers for the
sequences determined in this study are EF394357 (TAN2 consensus), EF394358
(TAN3 consensus), EF394356 (TAN1.910), DQ374657 (TAN2.69), DQ374658
(TAN3.1), and EF451055 (codon usage-optimized TAN1 gp160 env gene).
RESULTS
Construction of an infectious SIVcpzPts clone by concate-
nation of subgenomic fragments. In a first attempt to generate
an infectious molecular clone of SIVcpzPts, we concatenated a
proviral genome (TAN1) that had previously been amplified as
13 partially overlapping cDNA fragments from fecal virion
RNA of a wild-living chimpanzee (Ch-06) in Gombe National
Park (46, 50). Using existing amplicons and the full-length
TAN1 population sequence as a guide (46), we employed
strain-specific primers and extension overlap PCR to construct
a full-length provirus. As outlined in Fig. 1, this approach
involved multiple (up to four) consecutive rounds of PCR
amplification of the same genomic region, each consisting of 30
cycles. The final products comprised 5 and 3 proviral halves,
which were ligated at an internal BsmBI site to generate a
full-length provirus. The resulting clone (TAN1.24) contained
complete LTR elements on both ends of its genome (Fig. 1).
To examine the integrity of the TAN1.24 genome, the clone
was sequenced in its entirety. Like the TAN1 consensus se-
quence (46), TAN1.24 encoded a complete set of viral proteins
and intact regulatory elements, including promoter and en-
hancer regions in the LTR, the transactivating response (TAR)
element, the packaging signal, and the primer binding site.
However, TAN1.24 differed from the TAN1 consensus se-
quence in 76 nucleotides. Thirty-three of these represented
missense mutations which encoded amino acid substitutions in
Gag, Pol, Vif, Vpu, Env, and Nef protein sequences (Table 1).
In addition, there were four nucleotide sequence differences in
the 3 unique (U3) region of the viral LTR (Table 1). Inspec-
tion of the original TAN1 chromatograms indicated that only
17 of the 76 nucleotide differences represented previously
identified mismatches in regions of fragment overlap (46). The
remainder were thus likely introduced during the PCR-medi-
ated concatenation process.
TABLE 1. Nucleotide and amino acid sequence differences between the TAN1 consensus sequence and individual TAN1 molecular clones
TAN1
clone
No. of differences
Nucleotides
(LTR)
Amino acids
Gag Pol
Vif Vpr
Tat Rev
Vpu
Env
Nef
U3 R U5 p17 p24 PR RT IN Exon 1 Exon 2 Exon 1 Exon 2 gp120 gp41
24 4 0 0 1 4 2 9 4 4 0 0 0 0 0 1 1 6 1
177 4 0 1a 1 3 0 2 0 2 0 0 1b 0 0 0 2 3 (1b) 0
602 4 0 0 0 0 0 0 0 2 0 0 0 0 0 0 2 2 0
801 4 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 2 0
910 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
a Error introduced by PCR-mediated mutagenesis at position 138.
b Error introduced by PCR-mediated mutagenesis at position 8048.
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To examine its biological activity, TAN1.24 was transfected
into 293T cells and the resulting supernatants were tested in a
single-round infectivity (JC53-BL) assay (14, 42, 56). JC53-BL
cells express high levels of CD4, CCR5, and CXCR4 receptor
molecules and are stably transfected with -galactosidase and
luciferase reporter genes under the control of the HIV-1 LTR.
The infectious titer of any given virus stock can thus be deter-
mined by staining cultures for -galactosidase expression and
counting the number of blue cells. Analysis of transfection
supernatants in this assay indicated that TAN1.24-derived vi-
rus was noninfectious (Table 2). Moreover, pelleted virion
preparations lacked detectable RT activity (Table 2), and
cocultivation with human PBMCs failed to yield replicating
virus (Fig. 2). In all of these assays, the (CXCR4-tropic) HIV-
1/SG3 strain was used as a positive control (19). Thus, despite
encoding a complete set of uninterrupted reading frames,
TAN1.24 virus was replication defective.
Plasma-derived viral RNA is known to represent recently
produced (replicating) virus because of the short half-life of
infected CD4 T lymphocytes (25, 57). Assuming that viral
RNA in fecal samples is the result of ongoing replication in the
gut-associated lymphatic tissue (6, 34, 55), we reasoned that
fecal population sequences may represent a suitable template
for functional genome design. To test this hypothesis, we em-
ployed a stepwise mutagenesis approach that changed the
TAN1.24 sequence to that of its corresponding consensus se-
quence. Three proviral clones were generated; in these, the
number of amino acid differences from the consensus sequence
was reduced from 33 in TAN1.24 to 15 in TAN1.177, 6 in
TAN1.602, and 4 in TAN1.801 (Table 1). A fourth clone
(TAN1.910) was identical to the consensus sequence in all
protein coding regions as well as its entire LTR. All of these
viral constructs were found to produce virions that con-
tained measurable RT activity and mediated infection of
JC53-BL cells (Table 2). Moreover, there was a marked
inverse correlation between the number of missense muta-
tions and virion infectivity: the clone with the greatest num-
ber of amino acid sequence differences from the consensus
sequence (TAN1.177) produced the least infectious virus
(Table 2); conversely, the clone that matched the consensus
sequence in both protein and LTR sequences (TAN1.910)
yielded the most infectious virus (IU-per-particle ratio; Ta-
ble 2). Thus, changing the TAN1.24 sequence to that of its
consensus led to an improvement in viral infectivity of 3
orders of magnitude. Similar results were observed in pri-
mary human CD4 T-cell cultures, where TAN1.910 con-
sistently replicated to the highest titers, while TAN1.177 was
severely attenuated (Fig. 2). The titers of the remaining
clones (TAN1.602 and TAN1.801) reached intermediate
values. These results suggested that the predominant viral
species in fecal RNA is replication competent.
Generation of replication-competent SIVcpzPts proviruses
by chemical synthesis of fecal consensus sequences. To extend
these observations and to develop a more efficient strategy of
generating infectious molecular clones, we amplified SIVcpz
genomes from two additional chimpanzees and determined
their population sequences. Fecal samples were obtained from
wild-living members of the Kalande (Ch-64) and Mitumba
(Ch-45) communities in Gombe National Park, which had pre-
viously been shown to harbor diverse SIVcpzPts strains,
termed TAN2 and TAN3, respectively (48). An RT-PCR strat-
egy similar to that originally employed for TAN1 (46) was used
to amplify complete TAN2 and TAN3 genomes as sets of 15
and 14 partially overlapping subgenomic fragments (Fig. 3).
Direct sequence analysis of these RT-PCR amplicons yielded
very few positions of base mixtures (defined as “N” in sequence
chromatograms of both DNA strands; Table 3). However, a
considerable number of sequence differences between adjoin-
ing fragments in regions of sequence overlap were observed,
suggesting primer selection and/or limited template input (Ta-
ble 3). Approximately one-half of the observed ambiguities
affected the encoded amino acid (Table 3), but none intro-
duced stop codons or frameshift mutations. Both TAN2 and
TAN3 consensus sequences contained uninterrupted reading
frames for all structural and regulatory proteins as well as
intact regulatory elements. In phylogenetic trees of Gag, Pol,
Env, and Nef gene coding regions, TAN2 and TAN3 clustered
with TAN1, forming a well-supported geographic subclade
within the SIVcpzPts radiation. A representative tree of enve-
lope amino acid sequences is depicted in Fig. 4.
To test whether the TAN2 and TAN3 population sequences
could be used to generate infectious molecular clones, we
chemically synthesized their genomes as proviral halves (pur-
chased from Blue Heron Biotechnology, Bothell, WA) (Fig. 3).
For this purpose, it was necessary to select one nucleotide at
each position of sequence ambiguity, including differences in
FIG. 2. Replication potential of TAN1-derived molecular clones in
human CD4 T cells. The replication kinetics of TAN1.24, TAN1.177,
TAN1.602, TAN1.801, and TAN1.910 are shown in relation to a pos-
itive HIV-1 (SG3) control (y axis, nanograms of RT activity per ml of
culture supernatant). T cells enriched in CD4 from a human donor
were infected with transfection-derived culture supernatants equili-
brated by particle-associated RT activity (50 ng input).
TABLE 2. Biological activity of TAN1 molecular clonesa
Virus Infectious titer
b
(IU/ml)
RTc activity
(ng/ml)
Virion infectivity
(IU/ng RT)
TAN1.24 0 0 0
TAN1.177 1,100 66 17
TAN1.602 55,800 55 1,121
TAN1.801 69,050 57 1,235
TAN1.910 19,900 8 3,344
Mock 0 0 0
HIV-1/SG3 3,096,250 294 10,496
a Values are averaged from two independent experiments.
b Determined as the number of -galactosidase-expressing JC53-BL cells per
ml of transfection supernatant.
c Nanograms of particle-associated RT activity per ml of transfection super-
natant.
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regions of fragment overlap (Table 3). The following criteria
were used to make these choices. For ambiguous positions that
did not affect the corresponding amino acid, the most predom-
inant nucleotide (highest amplitude in the sequence chromato-
gram or most frequent nucleotide in repeat sequencing reac-
tions) was chosen. For mixtures that altered the corresponding
amino acid, the base that encoded the most common amino
acid residue in alignments of existing SIVcpz and HIV-1 pro-
tein sequences was selected. In the absence of an apparent
conserved amino acid (e.g., in hypervariable protein regions),
the nucleotide with the highest amplitude in sequence chro-
matograms was selected. Both TAN2 and TAN3 genomic
halves were synthesized with a restriction site introduced to
facilitate subsequent cloning into an appropriate plasmid vec-
tor. The integrity of the assembled proviruses (TAN2.1 and
TAN3.1) was confirmed by sequence analysis.
To examine their biological activity, transfection-derived
TAN2.1 and TAN3.1 viruses were tested for replication com-
petence in primary CD4 T-cell cultures from different human
donors (one representative experiment is shown in Fig. 5).
TAN3.1 virus replicated to high titers, with kinetics very similar
to those of HIV-1 (SG3) and SIVcpz (GAB1.1a) laboratory
controls (19, 28). In contrast, TAN2.1 was replication defective
in these same cultures (Fig. 5). To explore the reason(s) for
this phenotype, transfection-derived TAN1.910, TAN2.1, and
TAN3.1 stocks were purified and the resulting particles ana-
lyzed for protein composition by immunoblot analysis. These
experiments revealed no obvious defect in TAN2.1 particle
production and/or release: Western blots of pelleted virions
revealed comparable quantities of properly processed Gag
(p24), integrase (p32), and envelope (gp120) glycoproteins for
all three SIVcpzPts strains (Fig. 6A). However, TAN2.1-de-
rived virions lacked p51 and p66 bands (Fig. 6A, lane 2) and
contained only very low levels of particle-associated RT enzy-
matic activity (reduced by 3 orders of magnitude compared to
TAN1.910 and TAN3.1; not shown). These data suggested a
specific defect in the TAN2.1-encoded RT heterodimer.
To identify the underlying mutation, we reinspected all chro-
matograms containing TAN2 pol gene sequences. This analysis
identified one ambiguous site that had initially gone unrecog-
nized (Fig. 6B). At position 287 of the HIV-1 RT protein, the
TAN2.1 pol sequence chromatogram contained an A/G double
peak, encoding either a lysine (K) or a glutamic acid (E) in the
corresponding protein. Alignment of published SIVcpz and
HIV-1 RT sequences revealed that the lysine, but not the
initially selected glutamic acid, was highly conserved (Fig. 6C).
In fact, the lysine was invariant in all known SIVcpz strains as
well as HIV-1 group M, N, and O consensus sequences, sug-
gesting that it was essential for RT function (Fig. 6C). We thus
used site-directed mutagenesis to change the glutamic acid to
the conserved lysine residue. This substitution restored parti-
cle-associated RT activity as well as viral infectivity. The re-
sulting clone (TAN2.69), which differed from TAN2.1 in a
single nucleotide, produced virions that contained stable p66/
p51 RT heterodimers (Fig. 6A, right lane) and wild-type levels
of RT activity (not shown). Moreover, virus derived from the
TAN2.69 clone replicated efficiently in human CD4 T cells,
reaching maximal titers several days before virus derived from
TAN1.910 and TAN3.1 (Fig. 5). Thus, modification at a single
ambiguous site in the TAN2 population sequence restored its
biological activity. The crystal structure of the p66/p51 het-
erodimer places the lysine at position 287 in the “thumb” of the
HIV-1 RT complex (26). In the p51 subunit, this region is
involved in forming the dimer interface. One possibility, thus,
is that the glutamic acid replacement destabilized the p51/p66
interface, thereby rendering the heterodimer susceptible to
premature degradation. The absence of a detectable p51/p66
RT complex in pelleted TAN2.1 virions is consistent with this
hypothesis.
FIG. 3. Synthesis of SIVcpzPts proviruses from fecal RNA consensus sequences. The complete TAN2 and TAN3 genomes were amplified as
partially overlapping RT-PCR fragments (open boxes) from fecal virion RNA and sequenced without interim cloning (fragments are drawn to
scale). The resulting population sequences were used to synthesize the TAN2 and TAN3 genomes as proviral halves (black lines). Restriction
enzymes introduced into the sequence allowed their directional cloning into an appropriate plasmid vector (pCR-XL TOPO).
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Biological properties of the infectious SIVcpzPts clones.
Availability of the first infectious molecular clones of SIVcpz-
Pts allowed us to compare their baseline biological properties,
including coreceptor usage, replication capacity, cell tropism,
and neutralization phenotype, with those of representative
HIV-1 and SIVcpzPtt clones. Using the JC53-BL assay, we
found that the infectivity of TAN1.910, TAN2.69, and TAN3.1
(as well as that of GAB1.1a) was blocked by TAK779, an
antagonist for the CCR5 coreceptor, but not by AMD3100, an
antagonist specific for CXCR4 (Fig. 7). The three SIVcpzPts
strains thus resembled primary strains of HIV-1 (as well as the
single SIVcpzPtt clone) in their coreceptor preference. Virions
TABLE 3. Sequence ambiguities in TAN2 and TAN3 population sequences
Virus Amplicona Sequenceambiguityb
Position in
genome Protein Codon
Encoded amino
acidc
SIVcpzTAN2 B-C C-T 1068 p24 Gag 239 P
E-F T-C 2969 RT 257 I
E-F A-C 3017 RT 273 G
E-F C-T 3047 RT 283 I
*F G/Ad 3057 RT 287 E/K
F-G G-A 3869 RT 557 R
G-H A-G 4397 IN 173 R
G-H A-G 4407 IN 177 I-A
G-H T-C 4408 IN 177 I-A
H-I A-G 5149 Vif 154 I-V
H-I T-C 5154 Vif 155 V
J-K T-C 6104 Env 74 P
J-K G-C 6123 Env 81 D/A-H
*J-K A/C-A 6124 Env 81 D/A-H
J-K T-C 6125 Env 81 D/A-H
J-K G-A 6153 Env 91 E-K
*K G/T 6417 Env 179 V-F
K-L A-G 7165 Env 428 K-R
L-M G-A 7625 Env 581 K
SIVcpzTAN3 *B G/A 894 p24 Gag 27 V
*B C/T 909 p24 Gag 32 F
E-F G-T 3137 RT 313 E-D
*F A/T 3221 RT 341 I
*F G/A 3658 RT 487 R/K
G-H T-C 4241 IN 121 F
G-H G-A 4277 IN 133 A
G-H A-G 4280 IN 134 Q
G-H G-A 4292 IN 138 E
G-H A-G 4334 IN 152 E
G-*H T-C/T 4350 IN 158 L
G-H A-C 4406 IN 176 V
H-I A-G 5147 Vif 153 K-R
J-K C-T 6584 Env 236 Y
J-K A-C 6652 Env 259 Y-S
J-K G-C 6668 Env 264 V
J-K C-G 6728 Env 284 L
J-K A-C 6736 Env 287 K-T
J-K G-A 6737 Env 287 K-T
J-K A-G 6800 Env 308 E
J-K A-G 6831 Env 319 N-D
J-K G-A 6841 Env 322 R-K
J-K T-C 6872 Env 332 T
J-K C-T 6883 Env 336 T-I
J-K T-A 6890 Env 338 N-K
J-K T-G 6894 Env 340 F-V
J-K A-C 6957 Env 361 N-H
J-K G-T 6989 Env 371 K-N
J-K A-G 7002 Env 376 N-D
J-K A-G 7011 Env 379 R-E
J-K G-A 7012 Env 379 R-E
J-K G-A 7015 Env 380 R-K
J-K C-A 7022 Env 382 D-E
a The locations of TAN2 and TAN3 amplicons are shown in Fig. 3.
b Hyphens indicate nucleotide differences between adjoining fragments in regions of sequence overlap; slashes indicate positions of base mixtures; the latter are also
highlighted by asterisks on the corresponding amplicons.
c Amino acids encoded by the TAN2.69 and TAN3.1 infectious molecular clones are boldfaced.
d Initially unrecognized double peak in TAN2.1 sequence chromatogram.
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containing the CXCR4-tropic NL4.3 Env, the CCR5-tropic
YU2 Env, and the dual-tropic WEAU1.6 Env were analyzed in
parallel for control (Fig. 7).
We next compared TAN1.910-, TAN2.69-, and TAN3.1-de-
rived viruses in CD4 T-cell cultures from different human
donors. All three SIVcpzPts strains induced large syncytia and
were capable of establishing a productive infection in human
lymphocytes (Fig. 5 and not shown). However, in most CD4
T-cell cultures TAN1.910 replicated 1 to 2 orders of magnitude
less efficiently than the other two SIVcpzPts strains (Fig. 5 and
not shown). Since TAN1.910 is not identical in its sequence to
the TAN1 consensus, it is possible that some (or all) of the 40
remaining (albeit synonymous) nucleotide differences are re-
sponsible for this more attenuated phenotype. Alternatively,
the observed differences may reflect the normal range of rep-
lication fitness of naturally occurring SIVcpz strains in human
PBMCs. Biological characterization of additional SIVcpzPtt
and SIVcpzPts strains will be necessary to address this possi-
bility.
The replication capacity of TAN1.910-, TAN2.69-, and TAN3.1-
derived viruses was also tested in chimpanzee PBMCs. CD4
T-cell cultures were established from uninfected chimpanzees
housed at the Yerkes Regional Primate Center and coculti-
vated with (RT-equilibrated) transfection-derived viral super-
natants. As shown in Fig. 8, all three SIVcpzPts strains repli-
cated in chimpanzee CD4 T cells, although TAN1.910 again
grew to only modest titers compared to the other two strains.
Surprisingly, however, cultures from different chimpanzees
varied in their abilities to support SIVcpzPts replication (Table
4): TAN1.910 and TAN3.1 replicated in only a small fraction of
cultures tested (2/7 and 3/8, respectively), while TAN2.69 rep-
licated in each of four cultures analyzed, including two that did
not support the replication of TAN1.910 and TAN3.1. HIV-1/
SG3 and SIVcpzGAB1 replicated in all, or all but one, donor
cultures (8/8 and 5/6, respectively), thus excluding suboptimal
culture conditions as the reason for these differences (Table 4).
Based on these data, it seems clear that the host range of
TAN1.910 and TAN3.1 is more restricted than that of
TAN2.69 and that chimpanzee CD4 T cells appear to be
overall more refractory to SIVcpz infection than their human
counterparts.
Finally, we probed the three new SIVcpzPts strains for sen-
sitivity to neutralization by plasma from HIV-1-infected indi-
viduals, human neutralizing monoclonal antibodies, and solu-
ble CD4. These experiments showed that TAN1.910, TAN2.69,
and TAN3.1 were resistant to neutralization by a high-titer
human plasma pool (not shown), the CD4 binding site mono-
clonal antibody b12 (39) (not shown), and the coreceptor bind-
ing site antibody 17b (32, 60) (Fig. 9A). However, the P. t.
schweinfurthii viruses were sensitive to neutralization by two
human monoclonal antibodies (2F5 and 4E10) directed against
the membrane-proximal external region, indicating the conserva-
tion of these epitopes in SIVcpzPts (8, 66): 2F5 neutralized
TAN1.910, TAN2.69, and TAN3.1 with 50% inhibitory con-
centrations (IC50) of 5.5, 9.2, and 2.9 g/ml, respectively (Fig.
9B), while 4E10 yielded comparable IC50 values of 6.1, 6.7, and
1.7 g/ml (Fig. 9C). Finally, TAN1.910, TAN2.69, and TAN3.1
were also neutralized by soluble CD4, albeit at high IC50 values
of 395, 65, and 235 nM, respectively (Fig. 9D). Overall, the
neutralization phenotype of TAN1.910, TAN2.69, and TAN3.1
was very similar to that of primary HIV-1 isolates (5). In
contrast, SIVcpzGAB1 was sensitive to neutralization by hu-
man plasma (1:180), soluble CD4 (3.5 nM), and the CD4i
antibody 17b (1.1 g/ml) in the absence of pretreatment with
soluble CD4 (Fig. 9). The last indicates an increased formation
and/or exposure of the coreceptor binding site, which is typical
of tissue culture-adapted HIV-1 strains (Fig. 9, HIV-1/SG3).
FIG. 4. Phylogenetic relationships of TAN2 and TAN3 inferred
from Env amino acid sequences. The phylogenetic positions of the two
newly derived SIVcpzPts strains (boxed) are shown in relation to rep-
resentative strains of HIV-1 (groups M, N, and O; black), SIVcpzPtt
(red), and SIVcpzPts (blue). Viruses identified in wild chimpanzees
from Gombe National Park are indicated. Trees were inferred by the
Bayesian method; numbers on nodes are percent posterior probabili-
ties (only values of 95% and above are shown). The scale bar repre-
sents 0.1 substitutions per site.
FIG. 5. Replication potential of TAN1, TAN2, and TAN3 molec-
ular clones in human CD4 T cells. The replication kinetics of
TAN1.910, TAN2.1, and TAN3.1 as well as TAN2.69, which encodes
a Lys at position 287 of its RT protein, are shown in relation to those
of HIV-1 (SG3) and SIVcpzPtt (GAB1.1a) reference strains (y axis,
nanograms of RT activity per ml of culture supernatant). Enriched
CD4 T cells from four human donors were infected with transfection-
derived culture supernatants equilibrated by particle-associated RT
activity (50 ng), except for TAN2.1, which was used at maximal RT
activity. Results from one representative experiment are shown.
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DISCUSSION
In this paper, we report the construction of infectious mo-
lecular clones of SIVcpzPts from fecal RNA population se-
quences of three wild-living chimpanzees. We show that vi-
ruses derived from these clones express all viral proteins
required for productive infection of human and chimpanzee
CD4 T lymphocytes. We also show that the resulting viruses
are similar to primary HIV/SIV isolates in baseline biological
properties, including receptor and coreceptor usage and neu-
tralization phenotype. Although “live” viruses have previously
been generated by chemical synthesis of their genomic se-
quences (12, 53), this is the first example of the successful
reconstitution of infectious primate lentiviruses from RNA
sequences in stool samples collected from the jungle floor. This
approach expands the existing arsenal of noninvasive virus
detection methods and provides an important new tool to
unravel the biology of viruses that are otherwise not accessible
to investigation.
In our efforts to generate infectious SIVcpz clones from
fecal RNA consensus sequences, we explored two alternative
approaches. The first involved the concatenation of sub-
FIG. 6. Identification of an inactivating mutation in the TAN2.1 pol gene. (A) Western blot analysis of transfection-derived virions using Pol-,
Gag-, and Env-specific antibodies. Protein loading was equilibrated by RT activity, with 100 ng loaded to detect Pol and Gag proteins and 400 ng
loaded to detect Env (TAN2.1 was used at maximal RT activity). Bands corresponding to RT (p66 and p51), integrase (p32), capsid (p24), and
the extracellular envelope (gp120) protein are indicated. Lane 4 lacks a gp120 band because the HIV-1/SG3 Env protein failed to cross-react with
the SIVcpzPts-specific gp120 antiserum. Minor p32 migration differences correspond to predicted molecular weight differences of integrase
proteins from the different viruses. (B) Sequence chromatogram of the TAN2 pol gene revealing a site of sequence ambiguity (G/A double peak)
at position 3057 with differential coding potential (E or K at amino acid position 287 of the RT protein). (C) Alignment of available SIVcpzPts
(TAN1, TAN2, TAN3, and ANT), SIVcpzPtt (GAB1, GAB2, MT145, US, CAM3, CAM5, CAM13, EK505, MB66, and LB7), and HIV-1 (group
consensus) RT protein sequences (position 241 to 300) available from the Los Alamos HIV Sequence Database. Amino acids identical among all
RT sequences are shaded, with position 287 highlighted by an arrow.
FIG. 7. Coreceptor usage of SIVcpzPts strains. JC53-BL cells were
pretreated with AMD3100 (inhibitor of CXCR4), TAK779 (inhibitor
of CCR5), or both prior to addition of the virus preparations indicated.
Virus infectivity is plotted on the vertical axis as a percentage of the
untreated control. Pseudovirions containing the CXCR4-tropic NL4.3,
the CCR5-tropic YU2, and the dual-tropic WEAU envelope glycopro-
teins were included as controls.
FIG. 8. Replication potential of TAN1, TAN2, and TAN3 molec-
ular clones in chimpanzee CD4 T cells. The replication kinetics of
TAN1.910, TAN2.69, and TAN3.1 are shown in relation to HIV-1
(SG3) and SIVcpzPtt (GAB1.1a) reference strains (y axis, nanograms
of RT activity per ml of culture supernatant). Enriched CD4 T lym-
phocytes from chimpanzee C0462 were infected with transfection-
derived culture supernatants equilibrated by particle-associated RT
activity (50 ng).
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genomic RT-PCR fragments by extension overlap PCR. Al-
though this approach generated a full-length provirus with
seemingly functional genes, the resulting particles were repli-
cation defective. Reasoning that the PCR-based concatenation
process had introduced inactivating mutations, we explored
whether changing the proviral sequence to that of the corre-
sponding consensus sequence would restore its biological ac-
tivity. This was done in a stepwise fashion to determine how
many sequence changes were required. The results showed
that the defective phenotype of TAN1.24 was caused by sub-
stitutions throughout its genome, all of which contributed to its
replication defectiveness. Thus, the particular PCR-based con-
catenation scheme that we used does not seem suitable for
generating infectious molecular clones of SIV. However, it
may be possible to improve this approach by (i) concatenating
multiple cDNA fragments simultaneously, (ii) reducing the
number of cumulative amplification cycles, and (iii) using a
higher-fidelity polymerase. Such a revised protocol may pro-
duce a more manageable number of misincorporations (and
other ambiguities) that can more reasonably be addressed by
site-directed mutagenesis.
The second approach to generate infectious SIVcpz clones
involved the direct synthesis of fecal consensus sequences. The
rationale for this approach was severalfold. First, we inferred
from the mutagenesis experiments of TAN1.24 that fecal pop-
ulation sequences were a suitable template for functional ge-
nome design. Second, we assumed that fecal viral RNA, like
plasma viral RNA, represents replicating virus produced by
CD4 T cells in the gut-associated lymphatic system (6, 34, 55).
Finally, by generating a simple majority consensus sequence,
i.e., by determining the most frequent nucleotide at each po-
sition within the viral population, we expected to eliminate
most (if not all) inactivating mutations present among individ-
ual quasispecies members. These assumptions proved to be
FIG. 9. Sensitivity of SIVcpzPts strains to neutralization by human monoclonal antibodies and soluble CD4. Neutralization of virus infectivity
in JC53-BL cells (y axis) was scored as the concentration of human monoclonal antibodies 17b (A), 2F5 (B), and 4E10 (C) as well as soluble CD4
(D) required to reduce virus infectivity by 50% (IC50) (gray line).
TABLE 4. Replication potential of SIVcpzPts strains in chimpanzee CD4 T cellsa
Strain
Replication titersb (%) for chimpanzee:
C0415 C0526 C0522 C0726 C0495 C0724 C0535 C0462
HIV-1/SG3 100 100 100 100 100 100 100 100
GAB1.1a 8 100 Neg 25 ND 30 ND 59
TAN1.910 Neg Neg Neg Neg ND Neg 50 3
TAN2.69 ND ND ND 74 47 50 ND 77
TAN3.1 Neg Neg Neg Neg 12 Neg 120 100
a Replication titers are expressed relative to HIV-1/SG3 set to 100%; maximal titers are shown.
b ND; not done; Neg, negative.
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correct since the chemical synthesis of both TAN2 and TAN3
consensus sequences resulted in infectious viral genomes. The
fact that TAN2 required modification at one ambiguous site
highlights the need for careful inspection of the population
sequences for positions of base mixtures and a suitable algo-
rithm to resolve them. However, there are caveats to this virus
reconstruction approach. Amplification of viral sequences un-
der limiting dilution condition (e.g., because of partial sample
degradation, low fecal viral loads, and/or primer mismatch)
may generate sequences that are not fully representative of the
population consensus and may thus not be functional. Thus,
virus reconstruction from fecal consensus sequences should be
performed under conditions of high template input with suffi-
ciently cross-reactive primers.
Derivation of the first infectious molecular clones of SIVcpzPts
allowed us to compare their baseline biological properties to
those of HIV-1 and SIVcpz reference strains. These analyses
revealed a number of similarities with primary HIV-1 isolates,
including receptor and coreceptor preference, cell tropism,
and neutralization phenotype. However, differences in viral
infectivity and replication potential were also observed (Fig. 5
and 8). Most notably, TAN1.910 exhibited reduced replication
fitness compared to the other two SIVcpzPts strains in both
human and chimpanzee CD4 T cells, possibly because of the
remaining 40 (silent) nucleotide sequence differences from the
consensus sequence. The various SIVcpzPts strains also dif-
fered in their abilities to infect and replicate in CD4 T cells
from different chimpanzee donors (Table 4). Given that chim-
panzees are the natural host of SIVcpz, these results were
surprising. Moreover, the fact that PBMC cultures from every
human donor tested supported the replication of these same
SIVcpzPts strains suggests that chimpanzees more than hu-
mans vary in their susceptibilities to HIV/SIV infection. This
may explain the uneven distribution and low prevalence of
SIVcpz in certain chimpanzee communities (31, 48, 51). The
fact that GAB1 replicated in lymphocyte cultures of most
chimpanzees tested (Table 4) does not contradict this possibil-
ity, since this in vitro-adapted virus is not representative of
naturally occurring SIVcpz strains.
The noninvasive derivation of infectious molecular clones of
SIVcpz has important implications. Most importantly, this new
technology will permit the biological characterization of SIVs
(and their gene products) that have thus far only been found in
wild-living endangered primate species. Examples include the
SIVcpzPtt precursors of pandemic (group M) and nonpan-
demic (group N) HIV-1 (31) and the newly discovered SIVgor
lineage, infecting wild gorillas (54), as well as a multitude of
other SIVs from different primate species that to date have
been characterized only at the molecular level (4). Biological
analysis of these viruses promises to yield new insight into their
pathogenic potential as well as viral determinants that govern
cross-species transmission and host adaptation. Specifically,
the new technology should permit investigation of whether
certain strains or lineages of SIV are more prone than others
to infect, replicate, and spread in humans. To determine
whether such virological differences exist, it will be important
to test representative strains in more-complex biological sys-
tems, such as lymphoid (tonsil) explant cultures, which main-
tain their cell complexity and cytoarchitecture (20), are not
dependent on exogenous stimulation (20), and require func-
tional accessory proteins for efficient viral replication and cy-
topathicity (37, 43, 45). Humanized mouse models may also
represent an appropriate test system for dissecting biological
differences. An example is the recently described BLT mouse,
in which primary and secondary mouse lymphoid organs are
reconstituted with functional human B and T cells, monocytes,
macrophages, and dendritic cells (36). One prerequisite for
these studies is the availability of a sufficiently representative
set of infectious molecular clones that have not been subjected
to in vitro selection pressures.
In summary, we describe here a new strategy of deriving
replication-competent molecular clones of SIV from fecal con-
sensus sequences. This approach is conceptually similar to the
recent successful “resurrection” of biologically active ancestors
of endogenous human and ape retroviruses (15, 30, 33) and
emphasizes the advantage of consensus over individual viral
quasispecies, the latter of which may contain deleterious mu-
tations. In addition, the new strategy generates viruses that are
truly representative of SIVcpz strains in wild ape populations
since they are derived without in vitro propagation in human
cells. Analysis of such unadulterated “isolates” will permit the
identification of biological properties that are essential for
cross-species transmission and human infection. The present
study demonstrates the feasibility of such an undertaking and
provides a framework for generating the necessary reagents.
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